See more : Jufan Industrial Co., Ltd. (4584.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Citius Pharmaceuticals, Inc. (CTXR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Citius Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- PwrCor, Inc. (PWCO) Income Statement Analysis – Financial Results
- Taylor Maritime Investments Limited (TMI.L) Income Statement Analysis – Financial Results
- Entergy Utility Group, Inc. 1ST MTG 5% 52 (ENJ) Income Statement Analysis – Financial Results
- Proto Labs, Inc. (PRLB) Income Statement Analysis – Financial Results
- AFFIN Bank Berhad (5185.KL) Income Statement Analysis – Financial Results
Citius Pharmaceuticals, Inc. (CTXR)
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 194.32K | 179.68K | 164.87K | 152.36K | 893.00 | 1.75K | 2.63K | 1.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -194.32K | -179.68K | -164.87K | -152.36K | -893.00 | -1.75K | -2.63K | -1.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 14.82M | 17.66M | 12.24M | 8.81M | 8.60M | 6.56M | 2.94M | 2.93M | 1.80M | 437.97K | 492.14K | 705.81 | 0.00 |
| General & Administrative | 21.91M | 15.66M | 11.29M | 8.90M | 7.00M | 7.23M | 7.05M | 4.52M | 1.43M | 715.03K | 28.12K | 310.30 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.31K | 0.00 |
| SG&A | 21.91M | 15.66M | 11.29M | 8.90M | 7.00M | 7.23M | 7.05M | 4.52M | 1.43M | 715.03K | 28.12K | 19.62K | 25.64K |
| Other Expenses | 0.00 | 1.45M | 59.92K | 110.21K | 715.98K | 1.27M | 732.15K | 732.15K | 486.27K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 36.73M | 33.32M | 23.53M | 17.71M | 15.60M | 13.79M | 9.99M | 7.45M | 3.23M | 1.14M | 28.12K | 19.62K | 25.64K |
| Cost & Expenses | 36.73M | 33.32M | 23.53M | 17.71M | 15.60M | 13.79M | 9.99M | 7.45M | 3.23M | 1.14M | 28.12K | 19.62K | 25.64K |
| Interest Income | 1.18M | 251.40K | 261.83K | 68.07K | 52.66K | 0.00 | 806.00 | 806.00 | 3.07K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 251.40K | 10.84K | 15.67K | 16.44K | 15.84K | 850.79K | 8.99K | 7.50K | 0.00 | 3.25K | 2.39K | 0.00 |
| Depreciation & Amortization | 194.32K | 179.68K | 164.87K | 152.36K | 893.00 | 1.75K | 2.63K | 1.34K | 3.07K | 1.15M | 1.18M | 1.02K | 704.00 |
| EBITDA | -36.73M | -32.88M | -22.88M | -17.38M | -15.54M | -13.79M | -9.98M | -7.45M | -3.23M | 0.00 | 0.00 | -19.62K | -24.93K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -36.73M | -33.32M | -23.53M | -17.71M | -15.60M | -13.79M | -9.99M | -7.45M | -3.23M | -1.15M | -28.12K | -19.62K | -25.64K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.77M | 251.40K | 477.46K | 162.60K | 36.22K | 1.25M | -398.64K | -846.41K | 327.66K | 171.82K | 0.00 | -2.39K | -704.00 |
| Income Before Tax | -31.97M | -33.06M | -23.05M | -17.55M | -15.56M | -12.54M | -10.38M | -8.30M | -2.90M | -1.27M | -31.37K | -22.01K | -26.34K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 576.00K | 576.00K | 70.76K | 125.88K | 16.44K | 1.28M | 850.79K | 8.99K | 4.43K | -119.15K | -1.18M | -1.02K | 0.00 |
| Net Income | -32.54M | -33.64M | -23.13M | -17.67M | -15.58M | -12.54M | -10.38M | -8.30M | -2.90M | -1.27M | -31.37K | -22.01K | -26.34K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.23 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 | 0.00 | -0.04 | -0.03 | -0.04 |
| EPS Diluted | -0.22 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 | 0.00 | -0.04 | -0.03 | -0.04 |
| Weighted Avg Shares Out | 146.13M | 146.08M | 108.60M | 39.17M | 20.16M | 10.73M | 5.48M | 3.62M | 2.12M | 0.00 | 750.00K | 750.00K | 750.00K |
| Weighted Avg Shares Out (Dil) | 151.29M | 146.08M | 108.60M | 39.17M | 20.16M | 10.73M | 5.48M | 3.62M | 2.12M | 0.00 | 750.00K | 750.00K | 750.00K |
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022
3 Reddit Stocks to Buy in May
Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
Trading Penny Stocks on April 6th, MOBQ Stock Pushes Up
Shares of Citius jump 18% on new data for experimental lymphoma drug
Citius: 2022 Is A Year Of Catalysts
Citius Pharmaceuticals, Inc. to Present at Upcoming March 2022 Conferences
Source: https://incomestatements.info
Category: Stock Reports